Now showing items 253-272 of 3035

    • Biomarker investigations from the ATAC trial: the role of TA01. 

      Dowsett, M (2004-01)
      cDNA arrays and proteomic analyses have allowed the rapid identification of specific genes and proteins implicated in multiple tumor types. These molecules must then be validated as clinically relevant prognostic and ...
    • A biomarker model of sublethal genotoxicity (DNA single-strand breaks and adducts) using the sentinel organism Aporrectodea longa in spiked soil 

      Martin, FL; Piearce, TG; Hewer, A; Phillips, DH; Semple, KT (ELSEVIER SCI LTD, 2005-11)
      There is a need to develop risk biomarkers during the remediation of contaminated land. We employed the earthworm, Aporreetodea longa (Ude), to determine whether genotoxicity measures could be applied to this organism’s ...
    • Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial. 

      Hale, MD; Nankivell, M; Hutchins, GG; Stenning, SP; Langley, RE; Mueller, W; West, NP; Wright, AI; Treanor, D; Hewitt, LC; Allum, WH; Cunningham, D; Hayden, JD; Grabsch, HI (2016-11-22)
      BACKGROUND: Neoadjuvant chemotherapy followed by surgery is the standard of care for UK patients with locally advanced resectable oesophageal carcinoma (OeC). However, not all patients benefit from multimodal treatment and ...
    • Biopsy variability of lymphocytic infiltration in breast cancer subtypes and the ImmunoSkew score. 

      Khan, AM; Yuan, Y (2016-11-04)
      The number of tumour biopsies required for a good representation of tumours has been controversial. An important factor to consider is intra-tumour heterogeneity, which can vary among cancer types and subtypes. Immune cells ...
    • Blood lipids and prostate cancer: a Mendelian randomization analysis. 

      Bull, CJ; Bonilla, C; Holly, JM; Perks, CM; Davies, N; Haycock, P; Yu, OH; Richards, JB; Eeles, R; Easton, D; Kote-Jarai, Z; Amin Al Olama, A; Benlloch, S; Muir, K; Giles, GG; MacInnis, RJ; Wiklund, F; Gronberg, H; Haiman, CA; Schleutker, J; Nordestgaard, BG; Travis, RC; Neal, D; Pashayan, N; Khaw, KT; Stanford, JL; Blot, WJ; Thibodeau, S; Maier, C; Kibel, AS; Cybulski, C; Cannon-Albright, L; Brenner, H; Park, J; Kaneva, R; Batra, J; Teixeira, MR; Micheal, A; Pandha, H; Smith, GD; Lewis, SJ; Martin, RM (2016-06)
      Genetic risk scores were used as unconfounded instruments for specific lipid traits (Mendelian randomization) to assess whether circulating lipids causally influence prostate cancer risk. Data from 22,249 prostate cancer ...
    • Blood transfusion during radical chemo-radiotherapy does not reduce tumour hypoxia in squamous cell cancer of the head and neck. 

      Welsh, L; Panek, R; Riddell, A; Wong, K; Leach, MO; Tavassoli, M; Rahman, D; Schmidt, M; Hurley, T; Grove, L; Richards, T; Koh, D-M; Nutting, C; Harrington, K; Newbold, K; Bhide, S (2017-01-03)
      BACKGROUND: Patients with head and neck squamous cell carcinoma (HNSCC) undergoing radical chemo-radiation (CRT) frequently receive transfusion with packed red cells (PRCT) during radiotherapy on the basis that PRCT increases ...
    • BMJ Open Qualitylaunch 

      Bagenal, J (BMJ, 2017-07)
    • The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions 

      Antoniou, AC; Cunningham, AP; Peto, J; Evans, DG; Lalloo, F; Narod, SA; Risch, HA; Eyfjord, JE; Hopper, JL; Southey, MC; Olsson, H; Johannsson, O; Borg, A; Passini, B; Radice, P; Manoukian, S; Eccles, DM; Tang, N; Olah, E; Anton-Culver, H; Warner, E; Lubinski, J; Gronwald, J; Gorski, B; Tryggvadottir, L; Syrjakoski, K; Kallioniemi, O-P; Eerola, H; Nevanlinna, H; Pharoah, PDP; Easton, DF (NATURE PUBLISHING GROUP, 2008-04-22)
      Multiple genetic loci confer susceptibility to breast and ovarian cancers. We have previously developed a model (BOADICEA) under which susceptibility to breast cancer is explained by mutations in BRCA1 and BRCA2, as well ...
    • Body fatness and physical activity at young ages and the risk of breast cancer in premenopausal women 

      Magnusson, CMK; Roddam, AW; Pike, MC; Chilvers, C; Crossley, B; Hermon, C; McPherson, K; Peto, J; Vessey, M; Beral, V (NATURE PUBLISHING GROUP, 2005-10-03)
      We examined the relationship between body fatness, sports participation and breast cancer risk in 1560 premenopausal cases and 1548 controls, from three related population-based case - control studies in the UK. Half of ...
    • Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy. 

      Denis-Bacelar, AM; Chittenden, SJ; McCready, VR; Divoli, A; Dearnaley, DP; O'Sullivan, JM; Johnson, B; Flux, GD (2018-04)
      OBJECTIVE: The aim of this study was to calculate the range of absorbed doses that could potentially be delivered by a variety of radiopharmaceuticals and typical fixed administered activities used for bone pain palliation ...
    • The Borg family of Cdc42 effector proteins Cdc42EP1-5. 

      Farrugia, AJ; Calvo, F (2016-12-15)
      Despite being discovered more than 15 years ago, the Borg (binder of Rho GTPases) family of Cdc42 effector proteins (Cdc42EP1-5) remains largely uncharacterised and relatively little is known about their structure, regulation ...
    • Boronic acids-A novel class of bacterial mutagen 

      O Donovan, MR; Mee, CD; Fenner, S; Teasdale, A; Phillips, DH (ELSEVIER SCIENCE BV, 2011-09-18)
      Boronic acids and their esters are important building blocks in organic syntheses including those for drug substances and for which, as far as it can be determined, there are no published reports of testing for genotoxicity. ...
    • BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). 

      Kelly, JD; Tan, WS; Porta, N; Mostafid, H; Huddart, R; Protheroe, A; Bogle, R; Blazeby, J; Palmer, A; Cresswell, J; Johnson, M; Brough, R; Madaan, S; Andrews, S; Cruickshank, C; Burnett, S; Maynard, L; Hall, E; BOXIT Investigators (2018-09-29)
      BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) has a significant risk of recurrence despite adjuvant intravesical therapy. OBJECTIVE: To determine whether celecoxib, a cyclo-oxygenase 2 inhibitor, reduces the risk ...
    • The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate-Lactate Exchange in BRAF-Mutant Human Melanoma Cells. 

      Delgado-Goni, T; Miniotis, MF; Wantuch, S; Parkes, HG; Marais, R; Workman, P; Leach, MO; Beloueche-Babari, M (2016-12)
      Understanding the impact of BRAF signaling inhibition in human melanoma on key disease mechanisms is important for developing biomarkers of therapeutic response and combination strategies to improve long-term disease ...
    • Brain and Salivary Gland Tumors and Mobile Phone Use: Evaluating the Evidence from Various Epidemiological Study Designs. 

      Röösli, M; Lagorio, S; Schoemaker, MJ; Schüz, J; Feychting, M (2019-01-11)
      Mobile phones (MPs) are the most relevant source of radiofrequency electromagnetic field (RF-EMF) exposure to the brain and the salivary gland. Whether this exposure implies a cancer risk has been addressed in several ...
    • BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives 

      Seal, Sheila (2006-05)
      BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives Pathological mutations in BRCA1, BRCA2 and TP53 are associated with an increased risk of breast cancer. This study evaluated ...
    • The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. 

      Wang, Y; Bernhardy, AJ; Cruz, C; Krais, JJ; Nacson, J; Nicolas, E; Peri, S; van der Gulden, H; van der Heijden, I; O'Brien, SW; Zhang, Y; Harrell, MI; Johnson, SF; Candido Dos Reis, FJ; Pharoah, PD; Karlan, B; Gourley, C; Lambrechts, D; Chenevix-Trench, G; Olsson, H; Benitez, JJ; Greene, MH; Gore, M; Nussbaum, R; Sadetzki, S; Gayther, SA; Kjaer, SK; D'Andrea, AD; Shapiro, GI; Wiest, DL; Connolly, DC; Daly, MB; Swisher, EM; Bouwman, P; Jonkers, J; Balmaña, J; Serra, V; Johnson, N (2016-05)
      Breast and ovarian cancer patients harboring BRCA1/2 germline mutations have clinically benefitted from therapy with PARP inhibitor (PARPi) or platinum compounds, but acquired resistance limits clinical impact. In this ...
    • BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. 

      Shimelis, H; Mesman, RLS; Von Nicolai, C; Ehlen, A; Guidugli, L; Martin, C; Calléja, FMGR; Meeks, H; Hallberg, E; Hinton, J; Lilyquist, J; Hu, C; Aalfs, CM; Aittomäki, K; Andrulis, I; Anton-Culver, H; Arndt, V; Beckmann, MW; Benitez, J; Bogdanova, NV; Bojesen, SE; Bolla, MK; Borresen-Dale, A-L; Brauch, H; Brennan, P; Brenner, H; Broeks, A; Brouwers, B; Brüning, T; Burwinkel, B; Chang-Claude, J; Chenevix-Trench, G; Cheng, C-Y; Choi, J-Y; Collée, JM; Cox, A; Cross, SS; Czene, K; Darabi, H; Dennis, J; Dörk, T; Dos-Santos-Silva, I; Dunning, AM; Fasching, PA; Figueroa, J; Flyger, H; García-Closas, M; Giles, GG; Glendon, G; Guénel, P; Haiman, CA; Hall, P; Hamann, U; Hartman, M; Hogervorst, FB; Hollestelle, A; Hopper, JL; Ito, H; Jakubowska, A; Kang, D; Kosma, V-M; Kristensen, V; Lai, K-N; Lambrechts, D; Marchand, LL; Li, J; Lindblom, A; Lophatananon, A; Lubinski, J; Machackova, E; Mannermaa, A; Margolin, S; Marme, F; Matsuo, K; Miao, H; Michailidou, K; Milne, RL; Muir, K; Neuhausen, SL; Nevanlinna, H; Olson, JE; Olswold, C; Oosterwijk, JJC; Osorio, A; Peterlongo, P; Peto, J; Pharoah, PDP; Pylkäs, K; Radice, P; Rashid, MU; Rhenius, V; Rudolph, A; Sangrajrang, S; Sawyer, EJ; Schmidt, MK; Schoemaker, MJ; Seynaeve, C; Shah, M; Shen, C-Y; Shrubsole, M; Shu, X-O; Slager, S; Southey, MC; Stram, DO; Swerdlow, A; Teo, SH; Tomlinson, I; Torres, D; Truong, T; van Asperen, CJ; van der Kolk, LE; Wang, Q; Winqvist, R; Wu, AH; Yu, J-C; Zheng, W; Zheng, Y; Leary, J; Walker, L; Foretova, L; Fostira, F; Claes, KBM; Varesco, L; Moghadasi, S; Easton, DF; Spurdle, A; Devilee, P; Vrieling, H; Monteiro, ANA; Goldgar, DE; Carreira, A; Vreeswijk, MPG; Couch, FJ; for kConFab/AOCS Investigators; for NBCS Collaborators (2017-06-01)
      Breast cancer risks conferred by many germline missense variants in the BRCA1 and BRCA2 genes, often referred to as variants of uncertain significance (VUS), have not been established. In this study, associations between ...
    • BRCT domains of the DNA damage checkpoint proteins TOPBP1/Rad4 display distinct specificities for phosphopeptide ligands 

      Day, M; Rappas, M; Ptasinska, K; Boos, D; Oliver, AW; Pearl, LH (2018-10-08)